Announced Tue, 25 Aug, 2026 · 18:45 IST
FY2025-26 report shows 29% revenue growth and 105% PAT growth
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+2.0%1-day move
₹1455.60
prior close
₹1462.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.7+0.6+0.3+0.1+2.0+2.0+0.5+4.1+8.6+8.9+6.2+8.7——
Up moveDown movePending
AI summary
Sai Life Sciences filed its first Integrated Annual Report for FY2025-26; the 27th AGM is on September 17, 2026, at 10:30 a.m. via video conference. Revenue rose 29% to ₹2,192 crore, EBITDA grew 56%, and PAT increased 105% to ₹349 crore. Four commercial molecules were added, taking the portfolio to 34, while the CDMO pipeline stands at about 160 programs. FY2026-27 investment is planned at ₹1,100 to ₹1,300 crore, with 75% for capacity and 25% for capabilities, technology and AI.
Likely market impact
Growth and a larger commercial pipeline support earnings visibility, but record investment could increase spending and execution risks.